Alto Neuroscience, Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Amit Etkin (CEO) and Nicholas Smith (CFO) filed standard Sarbanes-Oxley certifications on August 12, 2026 for the Q2 2026 10-Q (quarter ended June 30, 2026). Both officers certified that the filing contains no untrue material facts, that financial statements fairly present the company's condition, and that disclosure controls and internal financial reporting controls are effective. No material weaknesses, deficiencies, or fraud were disclosed.
Why this rating
Routine quarterly certification; no substantive business event, transaction, or control issue disclosed. Standard compliance filing.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.